Clinical trials: Hepatitis C Virus (HCV)
Hepatitis C, Chronic
An Observational Study Examining the Use of Triple Combination Therapy With Boceprevir, Peginterferon Alfa-2a and Ribavirin in the Re-Treatment of Chronic Hepatitis C Patients
This prospective, national, multicenter, non-interventional study examined the use of triple combination therapy with boceprevir, pegylated interferon (peginterferon) alfa-2a and ribavirin in re-treating participants with…
- Trial name
- NCT02118597
- Testing
- Boceprevir, Simeprevir, Pegylated Interferon (Peginterferon) Alfa-2a
- Where
- 7 sites in Hungary
- Volunteers
- 19 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C Virus Infection
Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Chronic Hepatitis C Virus Infection Without Cirrhosis
The purpose of the study is to evaluate the efficacy and safety of a treatment regimen of 12 weeks or 8 weeks of simeprevir in combination with sofosbuvir in chronic hepatitis C virus (HCV) genotype 1 infected men and women…
- Trial name
- NCT02114177
- Testing
- Simeprevir, Sofosbuvir
- Where
- 40 sites in United States, Canada
- Volunteers
- 310 people
- Sponsor
- Janssen Infectious Diseases BVBA
Hepatitis C, Chronic
A Study of the Pharmacokinetics And Pharmacodynamics of Intravenously Administered Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C And Previous Non-Response to Pegylated Interferon And Ribavirin Combination Therapy
In this randomized, cross-over, open label study the correlation of Pegasys (peginterferon alfa-2a) pharmacokinetics after intravenous (iv) and subcutaneous (sc) administration with viral load and viral kinetics will be…
- Trial name
- NCT01337375
- Testing
- peginterferon alfa 2a [Pegasys], peginterferon alfa-2a [Pegasys]
- Where
- 5 sites in Germany
- Volunteers
- 31 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C
Hepatitis C Treatment in Idaho County Jails
To explore the feasibility of opt in Hepatitis C Virus (HCV) screening and initiation of HCV treatment during incarceration in county jails including; 1.
- Trial name
- NCT06533319
- Testing
- sofosbuvir/velpatasvir
- Volunteers
- 100 people
- Sponsor
- Eastern Idaho Public Health
Hepatitis C
ETHOS ENGAGE: Enhancing Treatment of Hepatitis C in Opioid Substitution Settings
The overall goals of the ETHOS II Project are to enhance hepatitis C virus (HCV) care in drug treatment clinics and needle and syringe programs (NSPs) in New South Wales and Australia, and to develop a translational framework for…
- Trial name
- ETHOS II (NCT03685045)
- Testing
- Campaign days
- Where
- 32 sites in Australia
- Volunteers
- 6,000 people, healthy volunteers welcome
- Sponsor
- Kirby Institute
Healthy
A Study of Drug-drug Interaction Between Ritonavir and TMC435350 in Healthy Volunteers
The purpose of this study is to evaluate the drug-drug interaction between steady-state concentrations of CYP3A4 or ritonavir and TMC435350 after its first and the last dose of the multiple dosing regimen and to explore the short…
- Trial name
- NCT01891851
- Testing
- TMC435350 200 mg, Ritonavir 100 mg
- Where
- Belgium
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Tibotec Pharmaceuticals, Ireland
Hepatitis B, Chronic, Adults
Molecular Epidemiology of Hepatitis B in Cayenne General Hospital, French Guiana
In South America, the prevalence of HBV is variable but high (> 8%) in the Amazon basin. In some areas, a third of HBsAg carriers are also infected with HDV, a major comorbidity factor.
- Trial name
- NCT04886102
- Testing
- An additional 5 mL venous blood tube taken from patients during their routine medical check-up at the hospital
- Where
- French Guiana
- Volunteers
- 400 people
- Sponsor
- Centre Hospitalier de Cayenne
HIV, Hepatitis C
Impact of an Antibiotic (Rifaximin) on Liver Scarring in HIV-Infected Patients With Liver Disease
For HIV-infected patients who have access to treatment, liver diseases are a major cause of morbidity and mortality. Hepatitis C is the most frequently encountered liver condition in this population.
- Trial name
- NCT01654939
- Testing
- Rifaximin
- Sponsor
- Douglas T. Dieterich
HCV Infection
Metabolic Viral Host Properties
Patients' metabolic properties may affect their immune response. This study aims to assess the effect of hosts' metabolic properties to viral infection.
- Trial name
- NCT00893308
- Volunteers
- healthy volunteers welcome
- Sponsor
- Hadassah Medical Organization
Hepatitis C, Chronic
A Study of Combination Treatment With Peginterferon Alfa-2a (Pegasys) Plus Ribavirin (Copegus) in Participants With Chronic Hepatitis C
This 3-arm study assessed the safety and efficacy of combination treatment with peginterferon alfa-2a + ribavirin in participants with chronic hepatitis C.
- Trial name
- NCT00800748
- Testing
- Peginterferon alfa-2a, Ribavirin
- Where
- 35 sites in Czechia, Slovakia
- Volunteers
- 372 people
- Sponsor
- Hoffmann-La Roche
Multiplex Testing of HIV, HBV, HCV and Syphilis, HIV
Clinical Performance Evaluation of MagIA IVD-MD Multiplex Testing (HIV/HBV/HCV/Syphilis)
Performance study to evaluate the clinical performance of the In-Vitro Diagnostics Medical Device MagIA H3S (a Multiplex Point-of-Care test for the combined detection of Human Immunodeficiency Virus (HIV), Hepatitis B and C and…
- Conditions
- Multiplex Testing of HIV, HBV, HCV and Syphilis, HIV, HBV, HCV
- Trial name
- MAGICS IBCS (NCT07170748)
- Where
- 2 sites in Côte d’Ivoire, Kenya
- Volunteers
- 2,950 people, healthy volunteers welcome
- Sponsor
- MagIA Diagnostics
Transplant; Failure, Heart, Hepatitis C
The Hepatitis C Transplant Collaborative
In this study we seek to test the hypothesis that safety and clinical outcomes after cardiac transplantation utilizing HCV NAT+ donor organs as currently performed are acceptable.
- Trial name
- NCT04493385
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Baylor Research Institute
Hepatitis C, Diagnostic Self Evaluation
HCV Self-testing in Malaysia
Self-testing with easy-to-use rapid diagnostic tests (RDTs) has been successfully used for diseases such as HIV. The availability of self-testing has been shown to increase testing rates and testing acceptability in diverse…
- Trial name
- NCT04982718
- Testing
- OraQuick® HCV Self-Test, First Response® HCV Self-Test
- Where
- Malaysia
- Volunteers
- 750 people, healthy volunteers welcome
- Sponsor
- Foundation for Innovative New Diagnostics, Switzerland
HIV Infections, Hepatitis C
Zidovudine Levels in HIV Infected Patients Being Treated for HCV
This study will test the amount of anti-HIV drugs in the blood cells of HIV-infected patients who are also being treated for hepatitis C virus (HCV) infection.
- Trial name
- NCT00059358
- Testing
- Ribavirin plus interferon alfa-2b, Ribavirin, Peginterferon alfa-2b
- Where
- Puerto Rico
- Volunteers
- 16 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis C, Chronic
Vaniprevir Plus PegIntron®/Ribavirin in Japanese Participants With Chronic Hepatitis C Who Are Non-responders to Previous Treatment (MK-7009-045)
The purpose of this study is to evaluate the safety, tolerability, and efficacy of vaniprevir (300 mg twice daily) given in combination with pegylated interferon alfa-2b (peg-IFN) and ribavirin (RBV) in Japanese participants with…
- Trial name
- NCT01405560
- Testing
- Vaniprevir, peg-IFN, ribavirin
- Volunteers
- 42 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C Virus Infection
Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic HCV Infection
The primary objectives of this study are to evaluate the efficacy, safety, and tolerability of sofosbuvir/velpatasvir (SOF/VEL) fixed dose combination (FDC) for 12 weeks in adults with chronic genotype 1, 2, 4, 5, or 6 hepatitis…
- Trial name
- ASTRAL-1 (NCT02201940)
- Testing
- SOF/VEL
- Where
- 80 sites in United States, Belgium and 7 more
- Volunteers
- 741 people
- Sponsor
- Gilead Sciences
Hepatitis
ANRS HC20 Effectiveness of an Optimized Anti HCV PegIFN-alpha2a + Ribavirin on Sustained Virological Response in Patients With HCV Genotype 1 and 4 Non Responders and Co-infected With HIV
The purpose of this study is to assess the effectiveness of an optimized anti HCV treatment (360μg per week of PegIFN-alpha2a + 18mg/kg/j of Ribavirin for 6 months.
- Trial name
- ETOC (NCT00901524)
- Testing
- Peg-interféron alpha 2a + ribavirin
- Where
- France
- Volunteers
- 58 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Chronic Hepatitis C, Obesity
Microarray Analysis of IFN-Induced Gene Expression in Obese and Non-Obese Patients With Chronic Hepatitis C
The response rate to interferon-based anti-viral therapy for chronic hepatitis C is lower in patients who are obese. However, it is not clear whether this is related to suboptimal dosing of the medication or alterated response in…
- Trial name
- NCT00322179
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Palo Alto Veterans Institute for Research
Hepatitis C
Use of a Patient-Centered Electronic App to Increase ED Patient's Knowledge on HCV to Improve the HCV Care Continuum
The investigators will conduct a randomized controlled clinical trial study in an urban emergency department in Baltimore to determine the impact of an educational app which is based on Leventhal's Common-Sense Model of Illness…
- Trial name
- NCT04162938
- Testing
- Patient-Centered Electronic App
- Where
- United States
- Volunteers
- 308 people
- Sponsor
- Johns Hopkins University
Chronic Hepatitis C
Albinterferon Alfa 2b Single Dose in Japanese Chronic Hepatitis C Patients
This study will evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of albinterferon alfa 2b (alb-IFN) single dose in Japanese chronic hepatitis C patients
- Trial name
- NCT00724776
- Testing
- Albinterferon alfa 2b
- Where
- Japan
- Volunteers
- 30 people
- Sponsor
- Novartis
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.